<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Clinical Practice</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Clinical Practice</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая практика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-3095</issn><issn publication-format="electronic">2618-8627</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">692161</article-id><article-id pub-id-type="doi">10.17816/clinpract692161</article-id><article-id pub-id-type="edn">STLZRJ</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">FUS-thalamotomy in the correction of tremors in fragile X-associated tremors/ataxia syndrome (FXTAS)</article-title><trans-title-group xml:lang="ru"><trans-title>ФУЗ-таламотомия в коррекции тремора при синдроме тремора/атаксии (FXTAS)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5805-486X</contrib-id><name-alternatives><name xml:lang="en"><surname>Katunina</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Катунина</surname><given-names>Елена Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>elkatunina@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7151-6544</contrib-id><contrib-id contrib-id-type="spin">8999-4537</contrib-id><name-alternatives><name xml:lang="en"><surname>Shipilova</surname><given-names>Natalia N.</given-names></name><name xml:lang="ru"><surname>Шипилова</surname><given-names>Наталья Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>natali.33@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-7073-5472</contrib-id><name-alternatives><name xml:lang="en"><surname>Bogomazova</surname><given-names>Veronika A.</given-names></name><name xml:lang="ru"><surname>Богомазова</surname><given-names>Вероника Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>v.r.n.k@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-2365-1186</contrib-id><name-alternatives><name xml:lang="en"><surname>Gryaznev</surname><given-names>Roman A.</given-names></name><name xml:lang="ru"><surname>Грязнев</surname><given-names>Роман Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>partiya2009@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2593-5481</contrib-id><contrib-id contrib-id-type="spin">2980-0173</contrib-id><name-alternatives><name xml:lang="en"><surname>Malykhina</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Малыхина</surname><given-names>Елена Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>elmalykhina@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3930-5998</contrib-id><contrib-id contrib-id-type="spin">6388-9644</contrib-id><name-alternatives><name xml:lang="en"><surname>Dolgushin</surname><given-names>Mikhail B.</given-names></name><name xml:lang="ru"><surname>Долгушин</surname><given-names>Михаил Борисович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>dolgushin.m@fccps.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2360-3261</contrib-id><contrib-id contrib-id-type="spin">3454-2665</contrib-id><name-alternatives><name xml:lang="en"><surname>Gumin</surname><given-names>Ivan S.</given-names></name><name xml:lang="ru"><surname>Гумин</surname><given-names>Иван Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>ivangumin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5337-8715</contrib-id><contrib-id contrib-id-type="spin">1737-2522</contrib-id><name-alternatives><name xml:lang="en"><surname>Dzhafarov</surname><given-names>Vidzhai M.</given-names></name><name xml:lang="ru"><surname>Джафаров</surname><given-names>Виджай Маисович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>mvijayd@hotmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal Center of Brain Research and Neurotechnologies</institution></aff><aff><institution xml:lang="ru">Федеральный центр мозга и нейротехнологий</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The Russian National Research Medical University named after N.I. Pirogov</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-03-28" publication-format="electronic"><day>28</day><month>03</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-05-01" publication-format="electronic"><day>01</day><month>05</month><year>2026</year></pub-date><volume>17</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>119</fpage><lpage>130</lpage><history><date date-type="received" iso-8601-date="2025-10-06"><day>06</day><month>10</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-11-16"><day>16</day><month>11</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-Вектор</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://clinpractice.ru/clinpractice/article/view/692161">https://clinpractice.ru/clinpractice/article/view/692161</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Tremor/ataxia syndrome associated with a brittle X chromosome is a rare neurodegenerative disease. <bold>CLINICAL CASE DESCRIPTION:</bold><bold> </bold>The article presents the clinical case of a 62 years old patient, suffering from hand tremors from the age of 5–7 with gradual onset of tremors in the head (with vocal jitter) and in the chin with further development of ataxia and mild dysarthria. After DNA-testing, the patient was diagnosed with increased levels of cytosine-guanine-guanine (CGG) trinucleotide repeats in the FMR1 gene of the Х-chromosome. Due to the absence of effect from conservative therapy and the unremitting progression of the severity of tremors, reaching the incapacitating levels, the patient underwent the stereotaxic destruction of the ventrolateral nucleus of the thalamus with focused ultrasound guided by magnetic resonance imaging (MRI) on the left side. During the process of the surgical intervention, a total of six ultrasonic exposures were delivered with achieving, based on the results of MR-thermometry, the average temperature levels of 57–60°С. The duration of treatment was 120 minutes. Right after the surgical intervention, significant clinical improvement was achieved: by 48% according to the Clinical Rating Scale for Tremor (CRST), by 80% according to the hemi-CRST (modified version of CRST for the evaluation of tremors on a single side of the body); the improvement of everyday activity according to the CRST (part С) was 87%. Thalamotomy with focused ultrasound (FUS-thalamotomy) did not cause any significant effect in this patient in terms of the aggravation of ataxia, of coordination or speech disorders. <bold>CONCLUSION:</bold> The presented clinical case demonstrates the complexity of setting the FXTAS diagnosis, as well as the necessity for the differential diagnostics of fragile Х-associated tremors and ataxia syndrome with a vast spectrum of hereditary diseases, manifesting with extrapyramidal symptoms and cognitive dysfunction. Due to the low efficiency of symptomatic medication therapy in FXTAS patients, the methods of functional neurosurgery should be considered, among which, recently more attention is gained by the MRgFUS method as the least invasive and as the safe one in the elderly individuals. As of today, the experience of performing the MRgFUS in patients with FXTAS syndrome is insignificant and contains the descriptions of single cases in foreign literature. This clinical case, the first experience of performing FUS-MRI in a patient with FXTAS syndrome in Russia, has demonstrated the potential of this approach, but further studies involving a larger number of patients and a longer observation period are certainly needed.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Синдром тремора/атаксии, ассоциированный с ломкой Х-хромосомой, — редкое нейродегенеративное заболевание. <bold>Описание клинического случая.</bold> В статье представлен клинический случай 62-летнего пациента, страдающего тремором рук с 5–7-летнего возраста с постепенным присоединением дрожания головы, голоса, подбородка и последующим развитием атаксии и лёгкой дизартрии. После ДНК-тестирования у пациента была выявлена экспансия тринуклеотидных повторов цитозин-гуанин-гуанин (CGG) в гене FMR1 в Х-хромосоме. В связи с отсутствием эффекта от консервативной терапии, неуклонным прогрессированием выраженности тремора, достигшим инвалидизирующего характера, пациенту проведена стереотаксическая деструкция вентролатерального ядра таламуса фокусированным ультразвуком под контролем магнитно-резонансной томографии (МРТ) слева. В процессе оперативного вмешательства проведено шесть ультразвуковых воздействий с достижением, по результатам МР-термометрии, средних температур 57–60°С. Длительность лечения составила 120 минут. Сразу после оперативного вмешательства достигнуто значительное клиническое улучшение: на 48% по клинической шкале оценки тремора CRST, на 80% по геми-CRST (модифицированная версия CRST для оценки тремора в одной половине тела); улучшение повседневной активности по шкале CRST (часть С) составило 87%. Таламотомия с помощью фокусированного ультразвука (ФУЗ-таламотомия) не оказала у данного больного существенного влияния на усугубление атаксии, координаторных или речевых расстройств. <bold>Заключение.</bold><bold> </bold>Представленный клинический случай демонстрирует сложность установления диагноза FXTAS, а также необходимость дифференциальной диагностики синдрома тремора и атаксии, ассоциированного с ломкой Х-хромосомой, с большим спектром наследственных болезней, проявляющихся экстрапирамидной симптоматикой и когнитивной дисфункцией. Низкая эффективность симптоматического медикаментозного лечения пациентов с FXTAS требует применения методов функциональной нейрохирургии, прежде всего — ФУЗ-МРТ как наименее инвазивного и безопасного у людей пожилого возраста. Данный клинический случай — первый опыт проведения ФУЗ-МРТ у пациента с синдромом FXTAS в России — показал потенциальную перспективность такого подхода, но, безусловно, необходимы дальнейшие исследования с участием большего количества пациентов и более продолжительным периодом наблюдения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>fragile X-associated tremor ataxia syndrome</kwd><kwd>Martin-Bell syndrome</kwd><kwd>MR-guided focused ultrasound</kwd><kwd>refractory tremor</kwd><kwd>case report</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>синдром тремора и атаксии, ассоциированный с ломкой Х-хромосомой</kwd><kwd>синдром Мартина–Белл</kwd><kwd>ФУЗ-МРТ</kwd><kwd>фармакорезистентный тремор</kwd><kwd>клинический случай</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57(1):127–130. doi: 10.1212/wnl.57.1.127</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003;72(4):869–878. doi: 10.1086/374321</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sherman S, Allen EG, Jesica S. Clinical manifestation and management of FXPOI. In: Tassone F, Hall DA, editors. FXTAS, FXPOI, and other premutation disorders. Basel: Springer Nature; 2016. P. 199–224. doi: 10.1007/978-3-319-33898-9_10</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hagerman RJ, Protic D, Rajaratnam A, et al. Fragile X-Associated Neuropsychiatric Disorders (FXAND). Front Psychiatry. 2018;9:564. doi: 10.3389/fpsyt.2018.00564</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hunter J, Rivero-Arias O, Angelov A, et al. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014;164A(7):1648–1658. doi: 10.1002/ajmg.a.36511</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004;291(4):460–469. doi: 10.1001/jama.291.4.460 EDN: GMEPVB</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. 2009;17(10):1359–1362. doi: 10.1038/ejhg.2009.51</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hagerman RJ, Berry-Kravis E, Hazlett HC, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065. doi: 10.1038/nrdp.2017.65</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Tassone F, Adams J, Berry-Kravis EM, et al. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):566–569. doi: 10.1002/ajmg.b.30482</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Seritan AL, Kim K, Benjamin I, et al. Risk factors for cognitive impairment in fragile X-associated tremor/ataxia syndrome. J Geriatr Psychiatry Neurol. 2016;29(6):328–337. doi: 10.1177/0891988716666379</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Paul R, Pessah IN, Gane L, et al. Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. Neurotoxicology. 2010;31(4):399–402. doi: 10.1016/j.neuro.2010.04.002</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Martínez-Cerdeño V, Lechpammer M, Lott A, et al. Fragile X-associated tremor/ataxia syndrome in a man in his 30s. JAMA Neurol. 2015;72(9):1070–1073. doi: 10.1001/jamaneurol.2015.1138</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Saldarriaga W, Salcedo-Arellano MJ, Rodriguez-Guerrero T, et al. Increased severity of fragile X spectrum disorders in the agricultural community of Ricaurte, Colombia. Int J Dev Neurosci. 2019;72:1–5. doi: 10.1016/j.ijdevneu.2018.10.002</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hall DA, Robertson E, Shelton AL, et al. Update on the clinical, radiographic, and neurobehavioral manifestations in FXTAS and FMR1 premutation carriers. Cerebellum. 2016;15(5):578–586. doi: 10.1007/s12311-016-0799-4 EDN: WGKIXW</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gokden M, Al-Hinti JT, Harik SI. Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). Neuropathology. 2009;29(3):280–284. doi: 10.1111/j.1440-1789.2008.00948.x</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Summers SM, Cogswell J, Goodrich JE, et al. Prevalence of restless legs syndrome and sleep quality in carriers of the fragile X premutation. Clin Genet. 2014;86(2):181–184. doi: 10.1111/cge.12249</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Au J, Akins RS, Berkowitz-Sutherland L, et al. Prevalence and risk of migraine headaches in adult fragile X premutation carriers. Clin Genet. 2013;84(6):546–551. doi: 10.1111/cge.12109</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wheeler AC, Bailey DB Jr, Berry-Kravis E, et al. Associated features in females with an FMR1 premutation. J Neurodev Disord. 2014;6(1):30. doi: 10.1186/1866-1955-6-30</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Juncos JL, Lazarus JT, Graves-Allen E, et al. New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS). Neurogenetics. 2011;12(2):123–135. doi: 10.1007/s10048-010-0270-5 EDN: QJNAEX</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Seritan AL, Ortigas M, Seritan S, et al. Psychiatric disorders associated with FXTAS. Curr Psychiatry Rev. 2013;9(1):59–64. doi: 10.2174/157340013805289699</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A(8):1009–1016. doi: 10.1002/ajmg.a.32060</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Winarni TI, Chonchaiya W, Sumekar TA, et al. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A. 2012;158A(10):2473–2481. doi: 10.1002/ajmg.a.35569</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovik J, Tolosa E, editors. Parkinson’s disease and movement disoders. Baltimore-Munich: Urban &amp; Schwarzenberg; 1988. P. 225–234.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119–126. doi: 10.1111/j.1532-5415.1986.tb05480.x</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Starkstein SE, Mayberg HS, Preziosi T, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139. doi: 10.1176/jnp.4.2.134</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Elben S, Dimenshteyn K, Trenado C, et al. Screen fast, screen faster: a pilot study to screen for depressive symptoms using the beck depression inventory fast screen in parkinson’s disease with mild cognitive impairment. Front Neurol. 2021;12:640137. doi: 10.3389/fneur.2021.640137</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Rutten S, van Wegen EE, Ghielen I, et al. Symptom dimensions of anxiety in Parkinson’s disease: replication study in a neuropsychiatric patient population. Clin Park Relat Disord. 2021;5:100117. doi: 10.1016/j.prdoa.2021.100117</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Hall DA, Birch RC, Anheim M, et al. Emerging topics in FXTAS. J Neurodev Disord. 2014;6(1):31. doi: 10.1186/1866-1955-6-31</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Leehey MA, Munhoz RP, Lang AE, et al. The fragile X premutation presenting as essential tremor. Arch Neurol. 2003;60(1):117–121. doi: 10.1001/archneur.60.1.117</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Peters N, Kamm C, Asmus F, et al. Intrafamilial variability in fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006;21(1):98–102. doi: 10.1002/mds.20673</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Cerquera C, Rumià J, Herrera JM, et al. A single case report of MR-guided focused ultrasound thalamotomy for tremor in fragile X-associated tremor/ataxia. Parkinsonism Relat Disord. 2016;28:159–160. doi: 10.1016/j.parkreldis.2016.04.002</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Fasano A, Sammartino F, Llinas M, Lozano AM. MRI-guided focused ultrasound thalamotomy in fragile X-associated tremor/ataxia syndrome. Neurology. 2016;87(7):736–738. doi: 10.1212/WNL.0000000000002982</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>García-de Soto J, Pouso-Diz JM, Fernández-Pajarín G, et al. MR-guided focused ultrasound for the treatment of tremor in fragile X-associated tremor/ataxia syndrome. Mov Disord Clin Pract. 2025;12(2):246–248. doi: 10.1002/mdc3.14270</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Campins-Romeu M, Conde-Sardón R, León-Guijarro JL, Sastre-Bataller I. Unilateral MRIgFUS thalamotomy: long-term follow-up in fragile X-associated tremor/ataxia syndrome. Neurologia (Engl Ed). 2024;39(8):710–712. doi: 10.1016/j.nrleng.2024.09.004 EDN: OAWWVU</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Di Luca DG, Ushe M, Norris SA, et al. Long-term outcome of unilateral magnetic resonance imaging-guided focused ultrasound for fragile X tremor ataxia syndrome. Mov Disord Clin Pract. 2025;2(7):991–994. doi: 10.1002/mdc3.70068 EDN: WVOMTI</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Salcedo-Arellano MJ, Wolf-Ochoa MW, Hong T, et al. Parkinsonism versus concomitant Parkinson’s disease in fragile X-associated tremor/ataxia syndrome. Mov Disord Clin Pract. 2020;7(4):413–418. doi: 10.1002/mdc3.12942 EDN: CLHAMC</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Tassone F, Greco CM, Hunsaker MR, et al. Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav. 2012;11(5):577–585. doi: 10.1111/j.1601-183X.2012.00779.x</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Yang JC, Niu YQ, Simon C, et al. Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study. Neuropsychopharmacology. 2014;39(12):2760–2768. doi: 10.1038/npp.2014.122</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Yang JC, Rodriguez A, Royston A, et al. Memantine improves attentional processes in fragile x-associated tremor/ataxia syndrome: electrophysiological evidence from a randomized controlled trial. Sci Rep. 2016;6:21719. doi: 10.1038/srep21719 EDN: WUSPLN</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Senova S, Jarraya B, Iwamuro H, et al. Unilateral thalamic stimulation safely improved fragile X-associated tremor ataxia: a case report. Mov Disord. 2012;27(6):797–799. doi: 10.1002/mds.24923</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Xie T, Goodman R, Browner N, et al. Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord. 2012;27(6):799–800. doi: 10.1002/mds.24958</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Ferrara JM, Adam OR, Ondo WG. Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation. Mov Disord. 2009;24(1):149–151. doi: 10.1002/mds.22354</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Mehanna R, Itin I. Which approach is better: bilateral versus unilateral thalamic deep brain stimulation in patients with fragile X-associated tremor ataxia syndrome. Cerebellum. 2014;13(2):222–225. doi: 10.1007/s12311-013-0530-7 EDN: YCNZQN</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Dos Santos Ghilardi MG, Cury RG, dos Ângelos JS, et al. Long-term improvement of tremor and ataxia after bilateral DBS of VoP/zona incerta in FXTAS. Neurology. 2015;84(18):1904–1906. doi: 10.1212/WNL.0000000000001553</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Alster P, Koziorowski DM, Za Bek M, et al. Making a difference-positive effect of unilateral VIM gamma knife thalamotomy in the therapy of tremor in fragile x-associated tremor/ataxia syndrome (FXTAS). Front Neurol. 2018;9:512. doi: 10.3389/fneur.2018.00512</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Bruno F, Catalucci A, Arrigoni F, et al. Comprehensive evaluation of factors affecting tremor relapse after MRgFUS thalamotomy: a case-control study. Brain Sci. 2021;11(9):1183. doi: 10.3390/brainsci11091183 EDN: JGQYDO</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Maragkos GA, Kosyakovsky J, Zhao P, et al. Patient-reported outcomes after focused ultrasound thalamotomy for tremor-predominant Parkinson’s disease. Neurosurgery. 2023;93(4): 884–891. doi: 10.1227/neu.0000000000002518 EDN: QEVJTD</mixed-citation></ref></ref-list></back></article>
